The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
All News
Article
Article
A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.
Article
US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.
Racial and Ethnic Determinants of Psoriatic Arthritis
A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.
https://t.co/uJD5DWZEwM https://t.co/5dg0ubQzvL
Danish registries study shows maternal Autoimmune Dzs (all) were assoc w/ incr risk of childhood cancers (OR=1.25, 95% CI 1.06, 1.47), acute lymphoblastic leukemia (OR =1.52), Burkitt lymphoma (OR=2.6) & CNS tumors (OR=1.45); same seen for RA mothers https://t.co/HQO972ch9R https://t.co/dDEJUo8unq
Racial and Ethnic Determinants of Psoriatic Arthritis
A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.
https://t.co/lHQxchTSyU https://t.co/AcXcpvuGI8
Eric Dein
Tweet
Enthesitis @lihi_eder
@RheumNow #RNL2024
- NSAID - 1st line in mild/isolated
- GC injxn but caution at Achilles
- MTX cond rec by GRAPPA (SEAM PsA)
- All bDMARD work vs PBO (TNFi, IL17, 12/23, 23, JAK, PDE4) - none superior
- IL17 v ADA: higher resol for IXE v ADA, but mixed data https://t.co/20KnQo4kpq
Richard Conway
Tweet
Advanced therapies in enthesitis. Don't believe the spin, they all work, no clear evidence that any agent is better than others. @lihi_eder @RheumNow #RNL2024 https://t.co/FwLMUmmClB
Eric Dein
Tweet
#RNL2024 @RheumNow
@lihi_eder on enthesitis
- ~1/3 PsA, SpA
- Enthesitis precedes onset of PsA in PsO, high u/s score ass. w/ RFs (BMI, nail dyst)
- Exam: tenderness (non-specific), as swelling uncommon. U/s helpful, but non-specif
- Marker of severity, higher risk of damage
Enthesitis precedes the onset of PsA in PsO patients. Dr. @lihi_eder discusses the importance of US in evaluation of these patients.
#RNL2024 @RheumNow https://t.co/bPLR7zpNe2
Nouf Al hemmadi
Tweet
@reumacia @RheumNow You are absolutely right. The point was not generally used for psoriasis ( not PsA). I was surprised my self 🤕.
Here is the slide again by Dr. Armstrong , great talk by the way. Let me know if you want the handout. https://t.co/C11Gkn2jho
Nouf Al hemmadi
Tweet
Unique and selective allosteric mechanism of deucravacitinib.
Eric Ruderman
#RNL2024
@RheumNow https://t.co/Zm3bYGR9JJ
Nouf Al hemmadi
Tweet
Diagnostic delay in SpA
2.3 years longer delay in diagnosis in women with PsA.
@lihi_eder
#RNL2024
@RheumNow https://t.co/d9ao8vvpa5
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
Eric Dein
Tweet
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
"If you are throwing a JAKi at these patients (see below) you are gonna make them better." Dr. Bruce Strober reporting on potential patients/disease states who may respond to JAKi. #RNL2024 @RheumNow https://t.co/bghPuszu5t
Eric Dein
Tweet
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
So why should you consider JAKi?
Multiple reasons provided by @JointMD including efficacy in domains, it's PO, reasonable safety.
#RNL2024 @RheumNow https://t.co/BgFjhb18Ad
Nouf Al hemmadi
Tweet
Random effect in ACR20 responses in male versus females in PsA.
No sex differences in ACR20 responses in patients on JAK/TYK2i .
@lihi_eder
#RNL2024
@RheumNow https://t.co/fgEORm0nKc
Nouf Al hemmadi
Tweet
Sex/Gender disparities in rheumatology.
@lihi_eder
#RNL2024
@RheumNow https://t.co/PB7zPYJHd0
